1. Home
  2. GRPN vs OMER Comparison

GRPN vs OMER Comparison

Compare GRPN & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GRPN

Groupon Inc.

HOLD

Current Price

$17.75

Market Cap

646.1M

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$9.33

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRPN
OMER
Founded
2008
1994
Country
United States
United States
Employees
1734
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
646.1M
772.8M
IPO Year
2011
2008

Fundamental Metrics

Financial Performance
Metric
GRPN
OMER
Price
$17.75
$9.33
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$33.67
$32.50
AVG Volume (30 Days)
1.7M
1.9M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.62
Revenue
$2,843,877,000.00
$29,868,000.00
Revenue This Year
$5.55
N/A
Revenue Next Year
$6.63
$233.22
P/E Ratio
N/A
$14.09
Revenue Growth
N/A
N/A
52 Week Low
$9.17
$2.95
52 Week High
$41.26
$17.65

Technical Indicators

Market Signals
Indicator
GRPN
OMER
Relative Strength Index (RSI) 52.74 32.25
Support Level $16.05 $8.27
Resistance Level $18.81 $12.06
Average True Range (ATR) 1.43 0.79
MACD -0.32 -0.11
Stochastic Oscillator 32.65 49.45

Price Performance

Historical Comparison
GRPN
OMER

About GRPN Groupon Inc.

Groupon Inc is a globalised, scaled two-sided marketplace that connects consumers to merchants. Its categories include Local: local inventory includes things to do, beauty and wellness, food and drink, home and automotive services, online services, as well as other types of experiences and services. Goods: Includes merchandise across multiple product lines, such as electronics, sporting goods, jewelry, toys, household items and apparel, and Travel: Features travel experiences at both discounted and market rates, including hotels, airfare, and package deals covering both domestic and international travel. The company operates in two segments, North America and International, with the majority of revenue from the Local category from the North America Segment.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: